12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lutathera: Phase III started

Advanced Accelerator began the open-label, international Phase III NETTER-1 trial to compare Lutathera given 4 times about 8 weeks apart plus 30 mg Sandostatin LAR octreotide vs. 60 mg Sandostatin LAR in about 200 patients...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >